よむ、つかう、まなぶ。
【参考資料6】抗微生物薬適正使用の手引き 第三版 補遺 (35 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_45318.html |
| 出典情報 | 厚生科学審議会 感染症部会 薬剤耐性（AMR）に関する小委員会 抗微生物薬適正使用（AMS）等に関する作業部会（第6回 11／19）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
57. Vidal L, Gafter-Gvili A, Borok S, Fraser A, Leibovici L, Paul M. Efficacy and safety of
aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled
trials. J Antimicrob Chemother. 2007 Aug;60(2):247-257.
58. Castanheira M, Sader HS, Mendes RE, Jones RN. Activity of Plazomicin Tested against
Enterobacterales Isolates Collected from U.S. Hospitals in 2016-2017: Effect of Different
Breakpoint Criteria on Susceptibility Rates among Aminoglycosides. Antimicrob Agents
Chemother. 2020 Apr;64(10):e02418-19.
59. Saito S, Hayakawa K, Tsuzuki S. et al. A Matched Case-Case-Control Study of the Impact of
Clinical Outcomes and Risk Factors of Patients with IMP-Type Carbapenemase-Producing
Carbapenem-Resistant Enterobacteriaceae in Japan. Antimicrob Agents Chemother. 2021
Feb;65(3):e01483-20.
60. van Loon K, Voor In 't Holt AF, Vos MC. A Systematic Review and Meta-analyses of the
Clinical Epidemiology of Carbapenem-Resistant Enterobacteriaceae. Antimicrob Agents
Chemother. 2017 Dec;62(1):e01730-17.
61. Paul M, Carrara E, Retamar P. et al. European Society of Clinical Microbiology and Infectious
Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant
Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin
Microbiol Infect. 2022 Apr;28(4):521-547.
62. Tumbarello M, Trecarichi EM, De Rosa FG. et al. Infections caused by KPC-producing
Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J
Antimicrob Chemother. 2015 Jul;70(7):2133-2143.
63. Gutierrez-Gutierrez B, Salamanca E, de Cueto M. et al. Effect of appropriate combination
therapy on mortality of patients with bloodstream infections due to carbapenemaseproducing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect
Dis. 2017 Jul;17(7):726-734.
64. Kaye KS, Marchaim D, Thamlikitkul V. et al. Colistin Monotherapy versus Combination
Therapy for Carbapenem-Resistant Organisms. NEJM Evid. 2023
Jan;2(1):10.1056/evidoa2200131.
65. Paul M, Daikos GL, Durante-Mangoni E. et al. Colistin alone versus colistin plus meropenem
for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria:
an open-label, randomised controlled trial. Lancet Infect Dis. 2018 Apr;18(4):391-400.
66. Perez F, El Chakhtoura NG, Yasmin M, Bonomo RA. Polymyxins: To Combine or Not to
Combine? Antibiotics (Basel). 2019 Apr;8(2):38..
67. Onorato L, Di Caprio G, Signoriello S, Coppola N. Efficacy of ceftazidime/avibactam in
monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria:
A meta-analysis. Int J Antimicrob Agents. 2019 Dec;54(6):735-740.
68. Fiore M, Alfieri A, Di Franco S. et al. Ceftazidime-Avibactam Combination Therapy Compared
to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to
Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis.
Antibiotics (Basel). 2020 Jul;9(7):388.
35
aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled
trials. J Antimicrob Chemother. 2007 Aug;60(2):247-257.
58. Castanheira M, Sader HS, Mendes RE, Jones RN. Activity of Plazomicin Tested against
Enterobacterales Isolates Collected from U.S. Hospitals in 2016-2017: Effect of Different
Breakpoint Criteria on Susceptibility Rates among Aminoglycosides. Antimicrob Agents
Chemother. 2020 Apr;64(10):e02418-19.
59. Saito S, Hayakawa K, Tsuzuki S. et al. A Matched Case-Case-Control Study of the Impact of
Clinical Outcomes and Risk Factors of Patients with IMP-Type Carbapenemase-Producing
Carbapenem-Resistant Enterobacteriaceae in Japan. Antimicrob Agents Chemother. 2021
Feb;65(3):e01483-20.
60. van Loon K, Voor In 't Holt AF, Vos MC. A Systematic Review and Meta-analyses of the
Clinical Epidemiology of Carbapenem-Resistant Enterobacteriaceae. Antimicrob Agents
Chemother. 2017 Dec;62(1):e01730-17.
61. Paul M, Carrara E, Retamar P. et al. European Society of Clinical Microbiology and Infectious
Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant
Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin
Microbiol Infect. 2022 Apr;28(4):521-547.
62. Tumbarello M, Trecarichi EM, De Rosa FG. et al. Infections caused by KPC-producing
Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J
Antimicrob Chemother. 2015 Jul;70(7):2133-2143.
63. Gutierrez-Gutierrez B, Salamanca E, de Cueto M. et al. Effect of appropriate combination
therapy on mortality of patients with bloodstream infections due to carbapenemaseproducing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect
Dis. 2017 Jul;17(7):726-734.
64. Kaye KS, Marchaim D, Thamlikitkul V. et al. Colistin Monotherapy versus Combination
Therapy for Carbapenem-Resistant Organisms. NEJM Evid. 2023
Jan;2(1):10.1056/evidoa2200131.
65. Paul M, Daikos GL, Durante-Mangoni E. et al. Colistin alone versus colistin plus meropenem
for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria:
an open-label, randomised controlled trial. Lancet Infect Dis. 2018 Apr;18(4):391-400.
66. Perez F, El Chakhtoura NG, Yasmin M, Bonomo RA. Polymyxins: To Combine or Not to
Combine? Antibiotics (Basel). 2019 Apr;8(2):38..
67. Onorato L, Di Caprio G, Signoriello S, Coppola N. Efficacy of ceftazidime/avibactam in
monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria:
A meta-analysis. Int J Antimicrob Agents. 2019 Dec;54(6):735-740.
68. Fiore M, Alfieri A, Di Franco S. et al. Ceftazidime-Avibactam Combination Therapy Compared
to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to
Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis.
Antibiotics (Basel). 2020 Jul;9(7):388.
35